Goldman Sachs Group Inc Eledon Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 258,106 shares of ELDN stock, worth $818,196. This represents 0.0% of its overall portfolio holdings.
Number of Shares
258,106
Previous 258,106
-0.0%
Holding current value
$818,196
Previous $874,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ELDN
# of Institutions
86Shares Held
37.1MCall Options Held
10.5KPut Options Held
66.8K-
Bvf Inc San Francisco, CA6.29MShares$19.9 Million0.94% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.57MShares$11.3 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.95MShares$9.36 Million0.0% of portfolio
-
First Light Asset Management, LLC Edina, MN2.33MShares$7.38 Million1.01% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L32.31MShares$7.31 Million2.06% of portfolio
About Eledon Pharmaceuticals, Inc.
- Ticker ELDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,756,800
- Market Cap $43.6M
- Description
- Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...